| European Case Law Identifier: | ECLI:EP:BA:2001:T042996.20010531 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 31 May 2001 | ||||||||
| Case number: | T 0429/96 | ||||||||
| Application number: | 86900423.4 | ||||||||
| IPC class: | C07K 7/10 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | SERINE PROTEASE INHIBITORS AND METHODS FOR ISOLATION OF SAME | ||||||||
| Applicant name: | Amgen Inc. | ||||||||
| Opponent name: | Teijin Limited | ||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Admissibility of the grounds of opposition under Article 83 and 56 (yes) Sufficiency of disclosure (yes) Novelty (yes) Inventive steps (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t960429eu1.html
Date retrieved: 17 May 2021
